Background: The selection criteria for phase III trials are often stringent. We aimed to determine how many advanced non-small-cell lung cancer (NSCLC) patients would have been eligible for phase III targeted therapy trials and the proportion receiving anticancer treatment. Results: A total of 62 patients were registered: 63% male; median age 71 years; 61% stage IIIB disease. Percentages that met criteria were: ECOG-4599 31%, AVAiL 24%, FLEX 69%, TALENT 27%, INTACT-1 50%, INTACT-2 42%, ESCAPE 39%, NEXUS 63% and MONET1 34%. Common reasons for ineligibility were insufficient life expectancy, poor performance status, abnormal bloods, proteinuria and associated cancer problems. Systemic therapies were received by 66% of patients and median survival was 10.3 months.
introduction Lung cancer is the leading cause of cancer death worldwide [1] . Non-small-cell lung cancer (NSCLC) represents 80% of all lung cancers, with a majority of these being stage IIIB or IV at diagnosis [2] . The 5-year survival of patients with advanced NSCLC is <2% even with the addition of platinum-based chemotherapy [3] . A number of phase III clinical trials have investigated combining chemotherapy with newer targeted therapy for first-line treatment of NSCLC patients in an attempt to improve survival.
The term 'targeted therapy' describes biological anticancer agents that act on specific targets in an attempt to limit tumour growth. Three classes that have been investigated in phase III studies in NSCLC are angiogenesis inhibitors, antagonists to the epidermal growth factor receptor (EGFR) family and multikinase inhibitors. The angiogenesis inhibitors, such as vascular endothelial growth factor (VEGF) inhibitors limit neovascularisation of tumours and thus limit the tumour's growth and its ability to metastasise [4] . The two main types of EGFR are anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors [5] . These inhibitors act on a series of pathways that would otherwise lead to increased cell survival, proliferation, metastasis and angiogenesis. A third potential targeted therapy group comprises multi-kinase inhibitors, which may act directly on the tumour or prevent angiogenesis by targeting the VEGF family and platelet-derived growth factor family [6] .
Bevacizumab is a VEGF inhibitor that has been shown to be effective in treatment of advanced NSCLC. This agent has been evaluated in combination with chemotherapy in two phase III trials. The American ECOG-4599 study provided evidence for overall survival (OS) benefit when comparing bevacizumab with paclitaxel and carboplatin to chemotherapy alone [7] . The European Avastin in Lung study (AVAiL) demonstrated an improvement in progression-free survival, response rates and response duration for patients treated with bevacizumab in combination with cisplatin and gemcitabine compared with patients treated with chemotherapy alone [8] .
The First-line in Lung cancer with ErbituX (FLEX) study compared cisplatin and vinorelbine alone with cetuximab (EGFR-specific monoclonal antibody) plus cisplatin and vinorelbine in patients over-expressing EGFR on immunohistochemistry. This study demonstrated a modest OS benefit in the cetuximab arm (11.3 versus 10.1 months, P = 0.04) [9] . However, the strategy of using a combination of chemotherapy and EGFR tyrosine-specific kinase inhibtors such as erlotinib or gefitinib has been disappointing. The Tarceva Lung Cancer Investigation (TALENT) trial in which cisplatin/ gemcitabine was compared with cisplatin/gemcitabine plus erlotinib failed to show a benefit in OS or time to disease progression [10] . Similarly, gefitinib in combination with chemotherapy in two separate studies [gefitinib in combination with gemcitabine/cisplatin in the Iressa NSCLC Trial Assessing Combination Treatment (INTACT-1) study [11] and carboplatin/paclitaxel in the INTACT-2 study [12] ] did not show any superiority in efficacy compared with chemotherapy alone.
Multi-kinase inhibitors such as sorafenib and AMG706 are currently being investigated in phase III trials in patients with advanced NSCLC: comparing sorafenib plus carboplatin/ paclitaxel with chemotherapy alone in the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy (ESCAPE) study, sorafenib plus cisplatin/gemcitabine with chemotherapy alone in the NSCLC research Experience Utilising Sorafenib (NEXUS) study and AMG706 plus carboplatin/paclitaxel with chemotherapy alone in the MOtesanib NSCLC Efficacy and Tolerability (MONET1) study.
As large randomised controlled trials provide evidence of efficacy of new treatments, the applicability of such results to all patients with a similar type and stage of cancer is important. The difficulty is that the eligibility criteria for participation in these trials are often very restrictive. This is particularly relevant to advanced NSCLC as patients often have multiple comorbidities or significant systemic effects due to their cancer. In addition, as costs associated with new molecular-targeted therapies are substantial to both the individual and the community, it is important to know that any efficacy data in regard to these treatments are broadly applicable to the potential target populations.
The effect such restrictive eligibility criteria has on the number of patients eligible for clinical trials has been previously investigated by our group in chemotherapy trials, where we found that only around a third of the advanced NSCLC population was eligible for participation in the trials [13] . To determine whether a similar effect occurs with targeted therapy trials, we designed a study to identify the number of advanced NSCLC patients that are eligible for the major targeted therapy trials. We compared the eligibility rate for targeted therapy trial with the actual rate of systemic therapy utilisation in the cohort. During the meeting, the following information was recorded: patient's demographic data, histological type of NSCLC, stage of the cancer according to the American Joint Committee on Cancer Edition 6, physician estimate of patient's life expectancy (>12 or <12 weeks), Eastern Cooperative Oncology Group (ECOG) performance status and patient's ability to give informed consent. Relevant blood test results, patient comorbidities such as cardiovascular disease, current medication, malignancy in the previous 5 years, prior treatment of any malignancy and features of the malignancy such as presence of any brain metastases, spinal cord compression and tumour invasion of blood vessels were obtained from the clinicians and/or the medical records. If data were not obtainable, a conservative estimate of the data was made assuming no abnormality.
The registry data for stage IIIB/IV NSCLC patients were then compared with the eligibility criteria available for ECOG-4599, AVAiL, FLEX, TALENT, INTACT-1, INTACT-2, ESCAPE, NEXUS and MONET1. Eligibility criteria for these trials were obtained from the Clinical Trials database of the USA National Institute of Health, trial protocols and publications. These eligibility criteria are summarised in supplemental Table 1 (available at Annals of Oncology online).
The actual systemic treatments that patients received were also reviewed retrospectively. Analysis involved simple summary statistics, using Excel. 
results
A total of 62 patients were included in this study: 63% male; median age 71 years; 61% stage IIIB and 76% ECOG performance 0-1. General patient characteristics including the histological types of NSCLC are summarised in Table 1 . Two patients had incomplete data in more than two categories, requiring conservative estimates to be made. Twenty-five patients (40%) did not have urine test results available and therefore, their results were assumed to be normal for urinary protein levels. The OS for this cohort was 10.3 months (95% confidence interval 6.6-14.1 months). Ten patients (16%) had an actual OS <12 weeks. Of the nine patients (15%) who had an ECOG performance status of 2, five had an estimated life expectancy of <12 weeks and three of these five patients died within that time frame. Table 2 shows patient eligibility for each trial. Patients were eligible for an average of 43% of clinical trials and failed on an average of 1 criterion. The trial with the most stringent criteria was AVAiL, with only 24% of patients eligible. The trial with the least restrictive criteria was FLEX, with 69% of patients eligible, assuming all patients had immunohistochemical tumour expression of EGFR, which was not available.
The major reasons for ineligibility are outlined in Table 3 . The largest percentage of patients (38%) was ineligible based on their estimated life expectancy being <12 weeks. An average of 34% of patients were excluded because of inadequate performance status. However, there were differing criteria for performance status among the trials, with FLEX, INTACT-1 and 2 including performance status 2 patients (15%). Abnormal blood results resulted in 32% of patients being ineligible. Only one patient did not have blood results available, and these were assumed to be normal. Twenty-nine per cent of patients with squamous cell carcinoma would have been excluded from the ECOG-4599 and AVAiL trials. Another important exclusion criterion was the presence of poor prognostic features associated with their cancer, such as the presence of brain metastases. These accounted for 30% of ineligibility. Co-morbidities led to 27% of patients being excluded.
Of the 62 patients, 41 (66%) received first-line systemic therapy; 18 (29%) went on to receive second-line therapy and 6 (10%) had third-line therapy. In the first-line setting, no patients received a targeted therapy in combination with chemotherapy outside a clinical trial; two patients received an EGFR tyrosine kinase inhibitor alone and one patient was enrolled in a first-line clinical trial examining the efficacy of vorinostat in combination with carboplatin/paclitaxel. The number of chemotherapy cycles received in the first-line setting ranged from 1 to 6 (mean five cycles). The two patients that received an oral EGFR tyrosine kinase inhibitor received up to 33 cycles where 4 weeks of treatment constitutes one cycle. Of the 41 patients who received first-line systemic therapy, 4 patients (10%) had grade 3 or more anaemia; 7 (17%) had grade 3 or more neutropenia and 2 (5%) had grade 3 or more thrombocytopaenia. One other patient participated in a clinical trial in the second-line setting involving the use of vandetanib. Table 4 details the specific systemic treatments the patients underwent during the course of their illness.
Reasons for patients not receiving treatments could not be accurately obtained for all patients as this information was reviewed retrospectively. However, some major reasons included major co-morbidities, cognitive dysfunction leading to inability to give informed consent and patient declining treatment.
discussion
Our previous study carried out in 2001-2002 determined that only 28%-35% of advanced NSCLC patients were eligible for the major combination chemotherapy trials [13] . The main reasons for exclusion then were co-morbidities (40%), ECOG performance status ‡ 2 (39%), symptomatic brain metastasis (8%) and previous malignancies (11%). Many patients were ineligible for multiple reasons. In the current study, we found an average of 43% (24%-69%) of patients were eligible for phase III trials using chemotherapy and targeted therapy regimens, suggesting that eligibility criteria may have been relaxed, despite more specific exclusions related to targeted therapies. However, excluding the two trials with the least restrictive eligibility (FLEX and NEXUS), the eligibility rate would have been 35% the same as in the previous study.
These eligibility rates are likely to be overestimates, due to our assumption that there were no abnormalities present if data were not available. For example, in the FLEX study, 15% of otherwise eligible patients became ineligible based on their EGFR immunohistochemistry status [9] , but our patients' EGFR status was unknown, so no patients were excluded on this criterion. Similarly, proteinuria was an exclusion criterion in four of the trials, but this information was unavailable in 40% of our patients.
There was large variability in eligibility criteria for comorbidities between the studies. For example, in the FLEX trial, the only co-morbidity exclusion criterion was a superior vena cava syndrome, the presence of which was thought to contraindicate hydration. None of our patients would have been excluded on the basis of this issue. In the NEXUS and ESCAPE trial, the only comorbidity exclusion was uncontrolled hypertension, which resulted in the exclusion of 3%-4% of our patients. The remainder of the trials would have excluded 30%-45% of our patients on co-morbidity criteria alone. This highlights a challenge in determining the best treatment for advanced lung cancer, as the proportion of patients with serious co-morbidities is substantially higher than in most other malignancies, with increased likelihood of cardiovascular diseases, chronic obstructive pulmonary disease and other malignancies [14] .
Similarly, in chemotherapy trials, patients with a performance status of 2 have been shown to have an increased incidence of adverse reactions and worse OS [15] . Only three trials (FLEX, INTACT-1 and 2) included these patients. Nine (15%) of our patients had an ECOG performance status of 2. Five of the nine had an estimated life expectancy <12 weeks and three of these five patients died within that time frame.
Estimation of survival was made by clinical judgement. The inaccuracy of physician's estimation of survival was demonstrated in this study where physicians deemed 38% of the patients ineligible due to insufficient life expectancy when only 16% actually had a survival <12 weeks. This is not a surprising finding as the inaccuracy of physician's estimation of patient's survival has been extensively reported in the literature [16, 17] . However, of the patients who were deemed ineligible due to insufficient life expectancy, other factors may have contributed to their ineligibility for most clinical trials: 42% had ECOG performance status of 2; 33% had ECOG performance status of 3-4 and 8% had brain metastasis. This highlights a potential concern where a small proportion of patients (17%) who may be eligible for clinical trials would be deemed ineligible due to under-estimation of their survival.
Even with our conservative approach to ineligibility, over half of all advanced NSCLC patients were not eligible for the clinical trials evaluated. This suggests that patients on trials are often so highly selected that they are not representative of the majority of patients with that stage of disease [18] . It is interesting to note that the survival rates between the reviewed studies are fairly similar despite the varied eligibility criteria applied.
Despite only 43% of our patients being eligible for the trials reviewed above, 66% of them actually went on to receive chemotherapy and/or targeted therapies. Only one received a targeted therapy in combination with chemotherapy (chemotherapy with vorinostat) and this occurred on a trial. Two patients (both non-smoking females of Asian ethnicity) received an EGFR tyrosine kinase inhibitor alone. Although it appears that there is an under-utilisation of targeted therapy in our patients, it is worthwhile noting that none of the targeted therapies mentioned in this study were reimbursed by the National Pharmaceutical Benefit Scheme in the first-line setting for NSCLC patients during the study period.
Of the 66% of patients who did receive anticancer treatment (chemotherapy), the mean number of cycles of first-line treatment was 5 (range 1-6) and median survival was similar to the clinical trials reported above at 10.3 months. This suggests that the majority of advanced NSCLC patients were able to tolerate treatment and may have benefited from being able to participate in a trial.
This study has a number of limitations; in particular, the small sample size of 62 patients that may affect median survival estimations. Furthermore, the treatment details were reviewed original articles Annals of Oncology retrospectively so not all information regarding the reasons for patients not receiving chemotherapy could be obtained. The strength of this study was that it represented 'the real world' as it was a single institution experience of all patients presented at the lung MDT meetings. We believe that a better balance needs to be achieved between only selecting patients with the greatest chance of benefit and including patients that would be considered well enough to be treated with the same agents off study. It is interesting to note that the OS was similar in the studies with more relaxed comorbidity eligibility compared with those with stricter criteria. While it is reasonable to determine efficacy of a treatment in highly selected patients, unless a drug is known to only work in a small subgroup of patients (e.g. those with a particular mutation), then phase III studies should include a more representative group of patients. This could be achieved by ensuring studies are powered to analyse predefined subgroups to determine who is more likely to benefit or having separate trials in more specific populations, as has been done for elderly patients and those with poorer performance status [15, 19] .
In addition, drug regulatory agencies should be made aware of the applicability of trial data to the target population when considering registration and reimbursement of a new chemical entity and the product information relating to a new drug should include the criteria by which patients were selected in pivotal randomised trials. In conclusion, most of the combination chemotherapy-targeted therapy trials for NSCLC patients have stringent eligibility criteria, excluding selection based on known mutation response, that affect the number of 'real world' patients that are eligible for these trials. This means that the results of many of these trials may not be generalisable to the majority of advanced NSCLC patients. It is difficult to practice evidencebased medicine for the majority of patients with advanced NSCLC as the evidence is not currently available. Future trials need to include a more representative population of NSCLC patients.
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